WO2007129428A1 - 幹細胞の単離方法 - Google Patents
幹細胞の単離方法 Download PDFInfo
- Publication number
- WO2007129428A1 WO2007129428A1 PCT/JP2006/325861 JP2006325861W WO2007129428A1 WO 2007129428 A1 WO2007129428 A1 WO 2007129428A1 JP 2006325861 W JP2006325861 W JP 2006325861W WO 2007129428 A1 WO2007129428 A1 WO 2007129428A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- stem
- stem cells
- stem cell
- isolated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0695—Stem cells; Progenitor cells; Precursor cells
Definitions
- the present invention relates to a method for isolating a stem cell, a stem cell isolated by the method, and
- the invention relates to the use of the stem cells.
- stem cells are used for research as “stem cells” by either method. Since such a conventional method is basically an artificial method, it cannot always be said that only true stem cells in vivo are used.
- stem cell therapy has already begun to be partly applied clinically, we have faced the fact that there is a lack of research on whereabouts of transplanted cells, in vivo kinetics, and risk of canceration.
- Non-Patent Document 1 Ruth Kirschstein & Lana R Skirboll, “Stem Cells: Scientific Progress and Future Research Directions J, National Institute of Healthy 2001, 1-106
- Non-Patent Document 2 Taylor et al., Cell, 102 ⁇ , 2000, 451-461
- An object of the present invention is to provide a method for prospectively isolating stem cells, stem cells isolated by the method, and therapeutic use of the stem cells or pharmaceutical use such as a vaccine. .
- stem cells can be efficiently isolated by labeling cell nuclei (eg, nuclear membrane). That is, stem cells labeled with cell nuclei are labeled even after division, and it has become apparent that they exhibit the self-renewal ability and long-lived characteristic of stem cells. For example, it is possible to efficiently isolate stem cells by labeling the nucleus of each cell in a heterogeneous cell population and selecting the labeled cells after cell division.
- cell nuclei eg, nuclear membrane
- the present invention enables visualization in a living state by labeling animal tissue stem cells using their essential functions, and uses genetic manipulation and artificial markers. In addition, it provides a simple isolation method in a fresh state (ie, without cell culture).
- the stem cell by applying the functional characteristics of the stem cell itself in a natural state, the stem cell is selectively labeled and isolated in a fresh state, as well as isolated by the present method.
- Stem cell bodies are included.
- the present invention relates to a method for prospectively isolating stem cells, stem cells isolated by the method, and pharmaceutical uses such as treatment or vaccine of the stem cells, more specifically, ,
- a method for isolating a stem cell from a cell population comprising the following steps (a) to (c):
- a method for isolating pathological stem cells comprising a step of isolating stem cells from a cell population prepared from diseased tissue by the method according to [1]
- a method for isolating somatic stem cells comprising a step of isolating stem cells from a cell population prepared from an organ tissue by the method according to [1]
- a method for isolating cancerous stem cells comprising the step of isolating stem cells from a cell population prepared from cancer tissue by the method according to [1],
- a method for examining whether a test cell is a stem cell comprising the following steps (a) to (c):
- test cell is a stem cell when the cell nucleus in the cell after division is labeled
- a method for selectively labeling stem cells comprising a step of labeling cell nuclei of cells
- a method for selectively visualizing stem cells in a living state comprising a step of bringing cells into contact with a nuclear nucleus labeling agent
- a method for observing stem cells in a living state comprising the step of visualizing stem cells by the method according to [10],
- a method for identifying a stem cell marker comprising the following steps (a) and (b):
- a method for identifying a cancerous stem cell-specific marker comprising the following steps (a) and (b):
- a method for identifying an antigen of a stem cell comprising the following steps (a) and (b):
- a method for identifying a stem cell-specific expression gene comprising the following steps (a) to (c):
- a method for identifying a target gene for treatment of a disease comprising the following steps (a) to (c):
- a method for treating a disease associated with the organ comprising transplanting an organ obtained by differentiating stem cells isolated by the method according to [1],
- a gene silencing treatment method comprising a step of suppressing the expression of a gene identified by the method according to [15] or [16],
- a method for screening an anticancer agent comprising the following steps (a) to (d):
- a stem cell wherein the labeled cell nucleus is labeled even after cell division, [26] the stem cell according to any one of [23] to [25], wherein the stem cell is a living cell [27] A somatic stem cell isolated from a cell population prepared from an organ by the method according to [1],
- a stem cell vaccine comprising an antigen of a stem cell isolated by the method according to [1] as an active ingredient
- a disease test agent comprising a stem cell marker identified by the method of [12] or [13] as an effective component
- a method for producing a labeled stem cell comprising a step of isolating a stem cell by the method according to any one of [1] to [5], [40] The production method according to [39], wherein the stem cell is a living cell, [41] a method for producing a stem cell-specific cell line, comprising the following steps (a) and (b):
- a method for producing an artificial organ comprising the step of differentiating stem cells isolated by the method according to [1],
- a method for producing a stem cell cytokine comprising as an active ingredient an antigen of a stem cell comprising the following steps (a) and (b):
- a method for producing an anticancer antibody against a specific organ comprising the following steps (a) and (b):
- stem cells isolated in a fresh state By using stem cells isolated in a fresh state by the method of the present invention, it becomes possible for the first time to analyze stem cells in a state closer to living organisms and to identify stem cell-selective markers. . In addition, since the in vivo dynamics of stem cells in living individuals can be visualized, it can also be applied to diagnosis of stem cell whereabouts, which is a risk factor in clinical application.
- this method is easy to apply to cancer cell lines (cell lines) that are established by culturing in vitro after collecting the tumor part of a cancer-bearing patient. This makes it possible for the first time to identify cancerous stem cells that have never worked. This method is the only method that can identify the true marker group of various stem cells. [0016] According to the present invention, the aspect of powerful stem cell research that cannot be analyzed forcefully by using artificial markers, which are not necessarily essential in the past, has been completely changed. You can study in a state close to. In addition, 1) It is the only way to establish a true stem cell marker by identifying the antigen and gene of the isolated stem cell.
- hepatocytes from the liver isolated by the method of the present invention proved to be the first cell in the world capable of forming a hepatocyte cord structure in a culture dish, and became a tissue-engineered human organ. It is a usable cell.
- Fig. 1 is a photograph of liver tissue stem cells immunostained by the BrdU labeling method.
- FIG. 2 is a photograph showing the migration of liver tissue stem cells in tissue repair. Liver tissue stem cells (brown: BrdU) proliferate and move toward repair of necrotic areas. Blue indicates type IV collagen.
- FIG. 3 is a photograph of observation of tumor formation by liver tissue stem cells.
- FIG. 4 is a photograph showing the labeling of hepatic tissue stem cells in a living mouse.
- FIG. 5 is a photograph showing the labeling of colon tissue stem cells in a living mouse.
- FIG. 6 is a photograph showing the labeling of liver tissue stem cells in a living mouse.
- FIG. 7 is a photograph showing isolation of liver tissue stem cells. SYTO GREEN negative cells did not form colonies, whereas SYTO GREEN high cells showed colony formation.
- FIG. 8 is a photograph showing hepatocyte cord-like construction using isolated hepatic tissue stem cells.
- FIG. 9 is a photograph showing the labeling of cancerous stem cells in the process of culturing cancer cell lines.
- FIG. 10 shows the isolation of cancerous stem cells from cancer cell lines.
- FIG. 11 is a schematic diagram showing the principle of the present invention.
- FIG. 12 is a photograph showing the labeling of hepatoma stem cells in a living mouse.
- FIG. 13 is a diagram and a photograph showing the isolation of cancerous stem cells from a cancer cell line.
- the present invention provides a method of isolating stem cells from a cell population.
- the “stem cell” in the present invention usually refers to a stem cell in a living state (in this specification, it may be described as “the stem cell of the present invention”).
- the stem cells of the present invention have the characteristic properties of (1) self-replicating ability and (2) long-term viability. This property remains even after the cells divide. That is, stem cells labeled with cell nuclei are in a state in which the cell nuclei are still labeled after cell division, and therefore, stem cells can be isolated using this label as an index.
- a preferred embodiment of the method for isolating stem cells of the present invention is a method characterized by labeling cell nuclei and selecting cells that have been labeled even after cleavage.
- the method of the present invention is preferably a method for isolating stem cells from a cell population, comprising the following steps (a) to (c).
- the step (a) is not particularly limited, but is usually performed by bringing a cell into contact with a substance capable of labeling the cell nucleus (sometimes referred to as "labeling agent").
- the cell nucleus refers to, for example, a nuclear membrane or a nucleic acid (including genomic DNA, histone, chromatin and the like), and preferably refers to the nuclear membrane. That is, in a preferred embodiment of the present invention, the nuclear membrane of a cell is labeled.
- labeling refers to labeling a cell nucleus to such an extent that it can be distinguished from a normal cell nucleus that is not labeled. That is, as long as the “label” in the present invention can be labeled in a manner distinguishable from normal cell nuclei, the labeling method and the type of substance for labeling are not limited.
- the “label” includes, for example, a label with a staining substance (color), a label with a fluorescent substance (dye), a label with an enzyme, a label with a radioactive substance, etc. It is a label with a substance.
- labeling agent for labeling cell nuclei in the method of the present invention
- a fluorescent dye for example, SYTO GREEN-Fluorescent Nuclear Acid Stain (Molecular 'manufactured by Probe Co., Ltd.) can be suitably shown.
- This substance is a low-affinity nucleic acid-binding substance that diffuses passively through the membrane of living cells and stains the nucleic acid (Chen A & McConnell SK, Cell 82: 631-341, 1995).
- fluorescent dyes such as fluorescent nanocrystals (manufactured by QUANTUM DOT), Cellestain-Hoechst 33258, Cyto-dye (Merck), etc. are available. These are not particularly limited.
- fluorescent nanocrystals manufactured by QUANTUM DOT
- Cellestain-Hoechst 33258 Cellestain-Hoechst 33258
- Cyto-dye Merck
- magnetic beads magnetic 'beads
- the labeling agent of the present invention is not particularly limited as long as it can label the cell nucleus (nuclear membrane, nucleic acid, etc.) of the cell, and any substance (dye, drug, reagent, etc.) can be used. Can do.
- a method of labeling cell nuclei of cells using the labeling agent described above is appropriately performed by those skilled in the art depending on the type of the labeling agent. It is possible . If the labeling agent used is commercially available, the cell nucleus can be appropriately labeled according to the attached instructions. Usually, it is performed by adding an appropriate amount of a labeling agent to the cell culture medium containing the cell population to be used. When the above SYTO GREEN is used as a labeling agent, specifically, cell nuclei can be labeled by the method described in Examples below.
- the substance capable of labeling cell nuclei can specifically label stem cells. That is, a new use of a cell nucleus labeling agent has been found. Therefore, the present invention provides a stem cell labeling reagent comprising a cell nucleus labeling agent as an active ingredient.
- the "cell population” in the above-described method of the present invention is not particularly limited in the tissue or organ from which the cell is derived.
- the cell population is prepared from (derived from) a normal organ tissue or a diseased tissue.
- the “cell population” of the present invention may be referred to as “cell group” or simply “cell”.
- a cell population used in the method of the present invention a cell population usually prepared from various organs can be preferably shown. From the cell population, so-called “somatic stem cells” can be isolated by the method of the present invention. The somatic stem cells in the present invention are also called adult stem cells.
- a somatic stem cell is an undifferentiated cell created inside a differentiated individual tissue, and can be recreated as described below. Any individual cell can be created. Somatic stem cells in vivo have the ability to replicate and manufacture the same cells as long as the living organism remains alive. The nature of is called "self-renewal”. Somatic stem cells usually differentiate first into precursor cells, which are further differentiated to have specific shapes and perform specific functions (for example, muscle cell contraction, nerve cell signal exchange). It grows into a “mature” cell. Somatic stem cells are present in the bone marrow, blood, cornea and retina of the eye, brain, skeletal muscle, dental pulp, liver, skin, stomach, intestinal lining and pancreas.
- somatic stem cells Much of the information about somatic stem cells comes from studies on hematopoietic stem cells isolated from bone marrow and blood. Hematopoietic stem cells that can produce blood have been extensively studied and applied to the treatment of various diseases. At present, the discovery of somatic stem cells that can produce all the cells of the body. It is very difficult to identify and isolate and purify somatic stem cells. It is also difficult to secure a sufficient number of somatic stem cells necessary for transplantation, and this cannot be replicated or propagated indefinitely by artificial culture.
- Somatic stem cells are found in all tissues that develop from the three primitive cell layers of embryonic germ cells (ectoderm, endoderm, and mesoderm).
- Somatic stem cells can proliferate in the body without long-term differentiation (this property is called “long-term self-renewal ability”), and some biological tissues It is also possible to create mature cells with specific shapes and functions.
- organs from which stem cells can be isolated by the method of the present invention include all organs present in living individuals. Specifically, brain, skin, hair follicle, eye, ear, tooth, Nail, nose, tongue, fat, muscle, blood vessel, lymph vessel, nerve, lymph node, spleen, bone, cartilage, lung, heart, liver, kidney, kidney, gastrointestinal tract, breast, thyroid, parathyroid, adrenal gland, prostate , Testis, ovary, uterus, or bladder.
- somatic stem cells unique to each organ can be obtained.
- a stem cell (pathological stem cell) involved in a disease can be isolated by the method of the present invention.
- a pathological stem cell is a somatic stem cell that has fallen into a pathological state (for example, canceration or establishment of a pathogen) for some reason.
- a cell that replicates for a long time while maintaining its pathological state is a somatic stem cell that has fallen into a pathological state (for example, canceration or establishment of a pathogen).
- the method of the present invention by isolating stem cells from tissues associated with various diseases, it is possible to obtain pathological stem cells that are targets for treatment of each disease. For example, as described later, by using siRNA or the like capable of suppressing the expression of a gene that is specifically expressed in the pathological stem cell, treatment for the disease (gene silencing therapy) can be performed. is there.
- cancerous stem cells can be isolated by the method of the present invention.
- a cancerous stem cell is a somatic stem cell that has become cancerous for some reason, and refers to a cell that produces a daughter cell (cancer cell) and replicates indefinitely as a cancer cell (Beachy PA et al. Nature 432: 324-331, 2004; Clarke MF & Fuller M. Cell 124: 1111-1115, 2006).
- cancerous stem cells that can be targets for selective treatment can be obtained for each cancer.
- treatment for specific cancer is performed by using siRNA or the like that can suppress the expression. Is possible.
- the species of the individual from which the cell population is derived is not particularly limited, and the method of the present invention can be performed on any organism as long as it is an organism having stem cells.
- the biological species derived from the stem cells that can be isolated by the method of the present invention is not particularly limited, and examples thereof include humans, mice, hamsters, rats, innu, monkeys, goats, and pigs.
- Cell division in the present invention includes “cell replication” and “cell proliferation”.
- a person skilled in the art can appropriately culture a desired cell according to the type of the cell.
- the stem cells of the present invention isolated under conditions with good noability preferably proliferate themselves and are considered to proliferate and differentiate with or without supplemental nutrients (see Examples below). ).
- the culture of the stem cells of the present invention is not particularly limited. However, for example, normal culture conditions, that is, RPMI medium or Dulbecco's modified Eagle medium Z ham F12 medium, 10% urine fetal serum, lOOU / Incubate with a culture medium containing mL penicillin G, lOOmg / mL streptomycin, and 4.5 g / L gnolecose at 37 ° C and 5% CO for 16 hours.
- it can be carried out by culturing for one week while changing the culture medium once every two days.
- the isolated cells are actually used for cell therapy clinically, for example, 1) Add support cells (fibroblasts), 2) Insulin, leukemia inhibitory factor (LIF), epithelium Add growth factors such as growth factor (EGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), or 3) Between cell adhesion and extension Methods such as using fibronectin or matrigel (three-dimensional culture) as the quality may be employed.
- fibronectin or matrigel three-dimensional culture
- step (c) selection of cells having a labeled cell nucleus is performed using the presence or absence of the label as an index.
- a person skilled in the art appropriately selects (selects) target cells (cells with labeled cell nuclei) using the presence or absence of the label as an indicator, depending on the type of substance (labeling agent) used for labeling. be able to.
- the labeling agent used is a fluorescent substance
- stem cells can be selected using a commercially available cell sorter using the presence or absence of the fluorescence as an index. More specifically, the stem cells of the present invention can be selected by the method described in the examples below.
- the method for selecting stem cells is not particularly limited to the method using the cell sorter.
- a cell suspension containing stem cells having the magnetic beads is passed through a magnet column (Veritas, Miltue Biotech, etc.), Only stem cells incorporating magnetic beads can be isolated easily. Nanomagnetic beads can easily differentiate between the magnetic strength of stem cells and normal cells by cell division. In addition, by using nanomagnetic beads as the labeling agent of the present invention, it is possible to follow the images of stem cells (magnetic beads MRI) by using MRI in an actual clinical setting.
- cells in which the presence of the label is detected that is, labeled Cells having cell nuclei are selected as stem cells.
- the stem cells isolated by the method of the present invention are preferably characterized in that they are living cells.
- the isolation method in the present invention can also be expressed as, for example, a stem cell selection method, a separation method, a selection method, a purification method, and the like.
- isolation method of the present invention a method for isolating mouse stem cells is shown below, but the method of the present invention is not particularly limited to this method.
- a fluorescent dye that stains the cell nucleus (nucleic acid, nuclear membrane, etc.) of cells is administered to mice, and a certain layer is added to the cell line. Thereby, all living cell nuclei are once fluorescently labeled. Some time lag occurs due to turnover of each organ and cell line.
- the fluorescent dye remains only in the nucleus of cells (ie stem cells) that are “self-renewal” in 1-2 weeks. Intensity of fluorescent dye, force due to toxicity The cells identified at this point remain labeled for at least one month.
- This method is a method that faithfully follows the laws of nature, in which only the stem cells are illuminated precisely from the viewpoint of the mouse or the cell itself, not from the human viewpoint.
- Stem cells isolated in the present invention include not only stem cells under normal or physiological conditions, but also stem cells under pathological conditions such as cancerous stem cells.
- the present invention includes a method for producing labeled stem cells, which comprises the step of isolating stem cells by the method of the present invention.
- the present invention provides a method for examining or discriminating whether or not a test cell is a stem cell, using the presence or absence of a labeled cell nucleus as an index.
- a preferred embodiment of the inspection method of the present invention is a method including the following steps (a) to (c).
- test cell is a stem cell when the nucleus of the cell after division is labeled.
- test cell refers to a cell or a cell subjected to detection (discrimination) as to whether or not it is a stem cell.
- the test cell is determined to be a stem cell, and when the cell nucleus is not labeled, the test cell is not a stem cell. Determined.
- stem cells are selectively labeled.
- a method for selectively labeling stem cells is also included in the present invention. This method is usually a method comprising a step of labeling the cell nucleus of a cell.
- Stem cells labeled by the above method are labeled after cell division, and the label remains for a long time.
- the term “long term” refers to a period that is significantly longer than when normal cells are labeled. For example, 2 days to 1 week or more, preferably 2 weeks or more, more preferably 3 weeks or more, and even more preferably. Indicates a period of one month or more.
- the labeling substance fluorescent dye, etc.
- the stem cells of the present invention and normal cells are distinguished using the presence or absence of the labeling substance as an indicator. It is possible.
- the cell may be divided at least once, but is preferably divided twice or more.
- a living stem cell can be labeled. That is, the present invention relates to a method for selectively visualizing stem cells in a living state.
- a preferred embodiment of the method is a method comprising a step of contacting a cell with a cell nucleus labeling agent.
- “visualization” is not necessarily limited only to observation with the naked eye. The case where the image is observed or visualized using various detection devices is also included in the “visualization” of the present invention.
- a person skilled in the art can appropriately select an observation means depending on the type of the substance used for the labeling. When a staining substance is used as the labeling agent, it can be observed using, for example, an optical microscope. In addition, when labeled with a fluorescent substance (dye), it can usually be observed using a fluorescence microscope.
- the present invention also relates to a method for observing the stem cells visualized by the method of the present invention in a viable state.
- a preferred embodiment of the method is a method comprising a step of visualizing stem cells by the method of the present invention.
- Image diagnosis is possible by visualizing the stem cells labeled by the method of the present invention in a living individual and observing their dynamics.
- Stem cells isolated by the method of the present invention can be used for various applications.
- stem cell markers can be identified using the stem cells of the present invention.
- the present invention provides a method for identifying a stem cell marker using stem cells isolated by the method of the present invention.
- a preferred embodiment of the method of the present invention is a method for identifying a stem cell marker, comprising the following steps (a) and (b).
- identifying a marker usually refers to finding a characteristic of a stem cell isolated by the method of the present invention that can be distinguished from other cells. Specifically, identification of a cell antigen or production of a cell-specific antibody can be exemplified.
- a sugar chain on the cell surface is identified, it becomes a very effective marker.
- a monoclonal antibody can be produced by immunizing another species with the stem cell itself isolated by the method of the present invention. In this case, an antibody that can be used for immunostaining or an antibody having a cell removal function can be established.
- cancer stem cell marker cancer stem cell-specific marker isolated by the method of the present invention
- early diagnosis of various cancers becomes possible. That is, the cancer stem cell-specific marker of the present invention is useful as a cancer diagnostic marker.
- a method for producing an antibody against a stem cell is also included in the present invention.
- the method for identifying an antigen of a stem cell of the present invention is, for example, a method comprising the following steps (a) and (b).
- a cancer stem cell-specific marker can be obtained by identifying a marker of the cell using a cancer stem cell isolated by the method of the present invention using a cell population prepared from a cancer tissue. it can.
- Markers eg, sugar chains and antibodies
- Markers identified by the method of the present invention are useful as diagnostic markers in actual clinical settings. For example, “By using the obtained cancer stem cell-specific glycan markers and antibodies, diagnosis for early detection of cancer is possible by examining the amount in blood and urine specimens. By labeling a typical sugar chain or antibody marker with nuclear medicine and administering it to a subject, diagnostic imaging can be performed using a general diagnostic imaging device such as CT, MRI, and PET / SPECT.
- the labeling substance when a substance that is safe to administer in vivo (for example, a safe fluorescent nucleic acid labeling substance) is used as the labeling agent of the present invention, the labeling substance is administered to the subject, After 2-3 weeks, the labeled residual stem cells can be detected image-wise using a fluorescence detection imaging device (eg, LED laser microscope, CCD camera, etc.) If there is a site forming an abnormal mass, It is super It can be diagnosed as early cancer. For example, if it is labeled in advance with a gastric Z colon camera test, it is possible to easily detect, diagnose, and treat early-stage cancer.
- a fluorescence detection imaging device eg, LED laser microscope, CCD camera, etc.
- the present invention relates to a method for identifying a stem cell-specific expression gene using stem cells isolated by the method of the present invention. For example, by suppressing the expression of a gene obtained by the method, it is possible to treat a disease related to stem cells.
- a preferred embodiment of the above method of the present invention is a method for identifying a stem cell-specific expression gene comprising the following steps (a) to (c).
- control cell usually refers to a cell other than a stem cell, for example, SY
- Examples include TO GREEN negative.
- step (c) it is preferable to select a gene whose expression state is enhanced in stem cells.
- a target gene for treatment of the disease is obtained. It is possible to identify.
- SYTO GREEN when used as the labeling agent of the present invention, another cell group that is isolated separately from SYTO GREEN positive and negative and serves as a so-called control. Search for differences in expression in at least 3 types of groups with (Standard). A gene that is particularly strongly expressed in SYTO GREEN strongly positive stem cells or a selection Gene that is expressed in the target is identified and used as a therapeutic target.
- a gene expression analysis method general known techniques such as a microarray (DNA chip) method, an ATAC-PCR method, an iAFLP method, a SAGE method, and a normal RT-PCR method can be used.
- the expression of the gene can be suppressed by RNA interference (RNAi), antisense molecule (nucleic acid), single Abuta molecule (nucleic acid) or the like. it can.
- RNAi RNA interference
- antisense molecule nucleic acid
- single Abuta molecule nucleic acid
- RNA nucleic acid
- siRNA RNA exhibiting an RNAi effect capable of efficiently suppressing the expression of the gene.
- the sequence of the RNA constituting the siRNA can be appropriately selected based on the sequence of the target gene, usually using commercially available software, for example. If the sequence of RNA constituting siRNA is determined, siRNA or siRNA expression vector can be appropriately prepared based on the sequence.
- siRNAs can be used alone or by preparing a drug by mixing the siRNA with atelocollagen or liposomes, and then administering them locally or systemically in vivo to treat gene silencing. Can be done.
- the present invention provides a gene silencing treatment method comprising the step of suppressing the expression of a gene identified by the method of the present invention.
- RNA interference (RNAi) method can be used.
- any technique that can suppress the expression of any gene can be used for the gene silencing treatment of the present invention.
- the present invention also provides a stem cell isolated by the method of the present invention. That is, the stem cell itself isolated by the method of the present invention is also included in the present invention.
- the present invention includes a method for concentrating or purifying stem cells contained in a cell population.
- the stem cell of the present invention is not necessarily limited to a cell population consisting only of stem cells, and may be a cell population substantially containing stem cells.
- Substantially containing stem cells is usually compared to the proportion of stem cells in the cell population prior to performing the method of the invention. It means that stem cells are contained to the extent that the proportion of stem cells is increased. Therefore, cell populations substantially containing stem cells are also included in the stem cells of the present invention. More specifically, for example, the proportion of stem cells in the cell population is usually 50% or more, preferably 80% or more, more preferably 90% or more, still more preferably 95% or more, and most preferably 99% or more. It is a simple cell population.
- a cell population containing the stem cells of the present invention with a purity of 80 to 90% can be obtained by an ordinary cell sorting technique.
- a narrower range set the fraction to be strictly isolated on a flow cytometer / cell sorter monitor
- cells containing the stem cells of the present invention with a purity of 99% or more It is possible to obtain a group.
- stem cell of the present invention include, for example, the following stem cells or stem cell lines.
- the stem cell of the present invention is usually characterized by being a living cell (live cell).
- Stem cell-specific cell line established from stem cells isolated by the method of the present invention
- the stem cell power of the present invention can also be appropriately established by a general technique such as “Robertson EJ. Biology of Reproduction 44: 238-245, 1991” in order to establish a cell line.
- a cell line can be established from the stem cells of the present invention by the following procedure. (1) Stem cells are isolated, (2) 3-5 days, feeder cells (fibroblasts) are added or cultured without addition, (3) colonies are formed, (4) Transfer to a culture dish of about 35 mm and incubate for an additional 4-7 days. (5) Maintain passage.
- the cell culture medium to be used is also capable of appropriately preparing an optimal medium in consideration of the type of cells.
- a stem cell line (for example, a stem cell-specific cell line) can be produced by establishing the stem cell of the present invention by the above method.
- the production method is also included in the present invention.
- a preferred embodiment of the method for producing a stem cell line of the present invention is a method comprising the following steps (a) and (b).
- stem cell of the present invention have the following properties.
- the stem cell of the present invention is preferably characterized in that a labeled cell nucleus is labeled even after cell division.
- stem cells of the present invention themselves can also be used as medicaments for disease treatment.
- the present invention provides a pharmaceutical composition comprising a stem cell isolated by the method of the present invention as an active ingredient.
- somatic stem cells are cells found in all organs' organs
- the pharmaceutical composition of the present invention targets all diseases (such as dysfunction).
- the pharmaceutical composition of the present invention includes, for example, neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, cardiovascular diseases such as myocardial infarction and cardiomyopathy, renal failure, liver failure, diabetes, cancer, spinal cord injury, frequent occurrence It is expected to have a therapeutic or preventive effect on autoimmune diseases such as multiple sclerosis.
- neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease
- cardiovascular diseases such as myocardial infarction and cardiomyopathy
- renal failure liver failure
- diabetes cancer
- spinal cord injury frequent occurrence
- autoimmune diseases such as multiple sclerosis.
- intractable diseases such as age-related macular degeneration, diabetic retinopathy, pulmonary fibrosis, inflammatory bowel disease, vision loss, hearing loss, taste
- An extremely diverse range of applications, such as disappearance, alopecia, or reconstruction after breast cancer surgery, can be considered.
- the antigen can be used as a stem cell vaccine.
- the antigen is preferably an antigen that exists specifically for stem cells (stem cell-specific antigen).
- stem cell-specific antigen e.g., a specific antigen obtained from cancerous stem cells (eg breast cancer) has a preventive effect on the onset and development of cancer (eg breast cancer).
- Specific antigens obtained from herpesvirus-infected stem cells have a preventive effect on herpes zoster recurrence after adulthood.
- specific antigens obtained from retinal vascular stem cells have a preventive effect against sudden blindness due to diabetic retinopathy.
- the antibody can be used as a so-called "antibody drug”.
- the antibody is preferably an antibody that specifically recognizes stem cells.
- Stem cell-specific antibodies obtained from cancerous stem cells eg breast cancer
- cancer eg breast cancer
- stem cell-specific antibodies obtained from hepatitis C virus-infected stem cells have a therapeutic effect on chronic hepatitis C virus ineffective with interferon therapy and acute / fulminant hepatitis due to hepatitis C virus.
- the progression of chronic hepatitis to cirrhosis and liver cancer are examples of chronic hepatitis to cirrhosis and liver cancer.
- the present invention provides a stem cell vaccine comprising an antigen of a stem cell isolated by the method of the present invention as an active ingredient, and an antibody against the stem cell of the present invention (preferably specifically recognizing the stem cell of the present invention.
- An antibody drug containing the antibody as an active ingredient is provided.
- the stem cell vaccine of the present invention or a method for producing an antibody against the stem cell of the present invention is also included in the present invention.
- a preferred embodiment of the method for producing a stem cell vaccine of the present invention is a method comprising the following steps (a) and (b).
- a preferred embodiment of the method for producing an antibody of the present invention is a method comprising the following steps (a) and (b). (a) a step of isolating stem cells by the method of the present invention
- an anticancer antibody against a specific organ can be produced.
- An antibody against a stem cell can usually be produced by a general antibody production technique using a stem cell or a part thereof as an antigen.
- a polyclonal antibody can be prepared by immunizing a immunized animal such as a rabbit with a purified stem cell of the present invention or a part of the peptide, collecting blood after a certain period, and removing the blood pipe. It is.
- Monoclonal antibodies are obtained by fusing antibody-producing cells of animal immunized with the above-mentioned cells or peptides and bone tumor cells, and isolating single clone cells (hybridomas) that produce the desired antibody. It can be prepared by obtaining an antibody.
- the antibody thus obtained can be used for purification and detection of the cells of the present invention.
- the present invention includes antibodies that bind to the stem cells of the present invention. By using these antibodies, it is possible to detect the presence site of the stem cell of the present invention or to determine whether or not the stem cell of the present invention is contained.
- the form of the antibody of the present invention is not particularly limited as long as it binds to the stem cell of the present invention or its antigen, in addition to polyclonal antibodies and monoclonal antibodies, human antibodies, humanized antibodies by gene recombination In addition, low molecular weight antibodies, antibody fragments thereof, and modified antibodies are also included. That is, the antibodies in the present invention include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies (scFv), humanized antibodies, and anti-antibodies such as Fab, Fa, F (ab ′) 2, Fc, Fv, etc. Contains body fragments. Such an antibody may be modified with PEG or the like, if necessary.
- It can also be produced as a fusion protein with ⁇ -galatatosidase, maltose binding protein, GST, green fluorescent protein (GFP), etc. so that it can be detected without using a secondary antibody. Further, by labeling the antibody with piotin or the like, it can be modified so that the antibody can be detected and recovered using avidin, streptavidin or the like.
- the stem cell of the present invention used as a sensitizing antigen for obtaining an antibody or a partial peptide thereof is not limited by the animal species from which it is derived, but it can be a mammal such as a mouse or a human. Preferably from human origin, particularly preferably from human origin.
- the antibody against the stem cell of the present invention suppresses the function of the cell by binding to the stem cell of the present invention, and is expected to have a therapeutic effect or an improvement effect on a disease caused by an abnormality of the stem cell, for example.
- a human antibody or a human type antibody is preferable in order to reduce immunogenicity.
- the present invention also relates to an artificial organ prepared from stem cells isolated by the method of the present invention.
- the artificial organ can be prepared by isolating stem cells that are usually present in S-tissue tissue by the method of the present invention and artificially inducing differentiation of the stem cells.
- the stem cell isolated by the method of the present invention is added (cultured) to a model as a "pseudo-organ" artificially constructed using a matrix, etc.
- An artificial organ that functions as an organ can be produced.
- a method for producing an artificial organ by the method of the present invention is also included in the present invention.
- a preferred embodiment of the method for producing an artificial organ of the present invention is a method including the step of differentiating the stem cells of the present invention.
- the present invention also relates to a therapeutic or prophylactic method comprising transplanting the stem cell of the present invention or an artificial organ obtained by differentiating the stem cell into an individual.
- the disease can be prevented or treated by administering the stem cell vaccine of the present invention or the antibody of the present invention to an individual.
- the present invention relates to a state of cell proliferation or cell death using a cancerous stem cell line (cancerous stem cell-specific cell line) and / or a normal cancer cell line isolated by the method of the present invention.
- a cancerous stem cell line cancerous stem cell-specific cell line
- a preferred embodiment of the method for screening an anticancer agent of the present invention is a method comprising the following steps (a) to (d).
- test compound used in this method is not particularly limited.
- natural compounds, organic compounds, inorganic compounds, single compounds such as proteins, peptides, etc. as well as compound libraries, gene library expression products, cell extracts, cell culture supernatants, fermentation microorganism products, marine products
- compound libraries include, but are not limited to, biological extracts and plant extracts.
- Contact of a test compound with a cell is usually performed by adding the test compound to a cell culture medium, but is not limited to this method.
- the test compound is a protein or the like
- “contact” can be performed by introducing a DNA vector expressing the protein into the cell.
- the state of cell proliferation or cell death in the above step (c) can be evaluated by, for example, culturing stem cells after step (b) and using the survival number of stem cells in the culture medium as an index. That is, when the number of survivors or the degree of proliferation is lower than that of the control, it is determined that cell proliferation is suppressed or cell death is promoted.
- control in the screening method of the present invention can be appropriately selected (set) by those skilled in the art as an appropriate “control” according to the embodiment.
- stem cells that are not contacted with a test compound, or normal stem cells can be used as a “control”. That is, any control compound that can determine the presence or absence of an effect is included in the “control” of the present invention.
- the present invention provides a drug (pharmaceutical composition) comprising the stem cell, stem cell vaccine, or antibody against the stem cell of the present invention.
- a drug pharmaceutical composition
- the drug of the present invention can also be formulated by a known pharmaceutical production method.
- a suitable carrier or medium generally used as a drug such as sterilized water or physiological saline, vegetable oil (eg, sesame oil, olive oil, etc.), colorant, emulsifier (eg, cholesterol), suspension agent ( Eg gum arabic), surfactant (eg polyoxyethylene hydrogenated castor oil surfactant), solubilizer (eg sodium phosphate), stabilizer (eg sugar, sugar alcohol, albumin), Or an appropriate combination with preservatives (eg, parabens), etc., and pharmaceutical preparations such as injections, nasal absorption agents, transdermal absorption agents, oral preparations and the like suitable for effective administration to the living body, preferably Can be prepared as an injection.
- vegetable oil eg, sesame oil, olive oil, etc.
- colorant emulsifier
- suspension agent Eg gum arabic
- surfactant eg polyoxyethylene hydrogenated castor oil surfactant
- solubilizer eg sodium phosphate
- stabilizer eg sugar, sugar alcohol,
- intraarterial injection intravenous injection, subcutaneous injection, etc.
- intranasal, transbronchial, intramuscular, or orally are performed by methods known to those skilled in the art. be able to.
- the dosage varies depending on the age, weight, symptoms, administration method, etc. of the patient, but those skilled in the art can appropriately select an appropriate dosage.
- the present invention also provides a kit for isolation and purification of stem cells, and a kit for producing stem cell vaccines, antibodies against stem cells or artificial organs of the present invention.
- the kit of the present invention can comprise, for example, a cell nucleus labeling agent, a medium for culturing cells, a culture solution, and the like.
- the kit includes a cell nucleus labeling agent, and a medium or culture solution as at least components.
- the kit of the present invention can contain the stem cells of the present invention as a sample (control). Furthermore, reagents for use in a method for detecting or sorting labeled stem cells can be included in the kit of the present invention.
- the stem cell vaccine of the present invention and the kit for producing antibodies against stem cells preferably comprise a cell nucleus labeling agent, a medium for cell culture, reagents for producing vaccines or antibodies, and the like as components. To do.
- the "medium” a medium generally used for culturing cells can be used.
- a person skilled in the art can easily know the basic composition of the above-mentioned “medium” from known literature or commercially available manuals.
- the kit of the present invention also includes various methods for separating the cells of the present invention, such as cells. Various reagents used for sorting can be included. In addition, the specifications of the kit of the present invention, instructions for the method, and the like can be appropriately packaged.
- “individual” usually refers to a human but may be an animal other than a human. That is, it is not particularly limited as long as it is an animal capable of isolating stem cells, and is usually a human, for example, non-human animals such as mice, hamsters, rats, nu, monkeys, goats, and pigs. I can do it. Stem cells obtained from Drosophila melanogaster and nematodes can be applied to more basic research fields.
- the present invention further relates to a method for labeling stem cells, which comprises the step of administering a cell nucleus labeling agent to an individual.
- a method for labeling stem cells which comprises the step of administering a cell nucleus labeling agent to an individual.
- the above-described method of the present invention can be used for distinguishing between stem cells and cells other than stem cells. Usually, by using the labeling level of the cells labeled by the above method of the present invention as an index, it is possible to distinguish stem cells from other cells. As shown in the examples described later, the above-described method of the present invention can appropriately identify, for example, three types of cells: cancer stem cells, normal stem cells, and normal cancer cells.
- stem cells can be selectively isolated from a group of cells containing a plurality of types of cells by the method of the present invention.
- stem cells labeled by the method of the present invention as an index, it is possible to screen for substances that selectively kill stem cells, or substances that inhibit or increase the proliferation of stem cells.
- Example 1 Example of labeling tissue sections of tissue stem cells in living mice: liver
- brom justifyidine (Brd U; Sigma_Aldrich, 5 mg / mL, 20 ⁇ LZ) was injected subcutaneously every 12 hours for a total of 3 times, and then followed up to 8 weeks of age over time.
- BrdU is a thymidine analog that is incorporated into DNA during the S phase of the cell cycle (Taylor et al. Cell 102: 451-461, 2000). Over time, mice were sacrificed and their livers were collected.
- a part of the collected second lobe of the liver was embedded in a freezing embedding agent OCT compound (manufactured by Miles), and a frozen block was prepared with liquid nitrogen.
- a section having a thickness of 6 ⁇ m was prepared using the cryoblocking force cryostat (manufactured by Microm). The obtained sections were fixed with acetone (Wako) for 10 minutes, washed with phosphate buffer, and immunostained using the Brd U staining kit (Zymed) according to the attached document. BrdU was removed. The inserted cells were observed with an optical microscope (Leica).
- Fig. 1 shows a typical example of an immunostained image of the obtained liver tissue.
- BrdU-labeled residual cells were detected in a slight amount up to 8 weeks of age for at least the observed period.
- all hepatocytes disappear and are replaced with new hepatocytes.
- BrdU-labeled residual cells are present in several percent of all hepatocytes, it was found that these label-retained cells are small cell populations that satisfy the properties of stem cells.
- Example 2 The 8-week-old mouse prepared in Example 1 was intraperitoneally injected with carbon tetrachloride (50 x L / 100 g body weight; manufactured by Sigma-Aldrich). Over time, the liver was treated in the same manner as in Example 1. The immunostaining images were examined. This experimental system is most commonly used as a liver injury-regeneration model (Morrison GR. Arch. Biochem. Biiphys. 111: 448, 1965) where hepatocyte regeneration is promoted after inducing extensive hepatocyte necrosis. It is an experimental system. One day after the administration of tetrasalt-carbon, extensive hepatocyte necrosis was observed, while rapid proliferation of the remaining hepatocytes was observed (Fig. 2). On the third day when hepatocyte regeneration after injury was promoted, tissue stem cells clearly increased in a lump and an image of repairing necrotic tissue was observed. That is, the BrdU-labeled remaining cells were functionally considered to be tissue stem cells.
- Example 3 Evidence for tissue stem cells: hepatocarcinogenesis
- DEN N-nitrosodiethylamine; 50 ⁇ gZ, Sigma-Aldrich
- DEN N-nitrosodiethylamine
- induced hepatocellular carcinoma Yang X et al. Int J Cancer 118: 1869-1876, 2006.
- liver tissue sections were prepared in the same manner as in Example 1, and the dynamics of tissue stem cells were analyzed by BrdU staining. The results are shown in Figure 3.
- a macroscopic tumor image has not yet been formed, but histologically, an ultra-early tumor image centered on stem cells was observed. In this example, it was shown that canceration occurs from tissue stem cells.
- SYTO GREEN-Fluorescent Nuclear Acid Stain Is a fluorescent dye that penetrates nucleic acids and nuclear membranes to stain all living cell nuclei of 2-day-old C57BL / 6 mice (CLEA Japan). Probes, 50 nM, 20 ⁇ L / mouse) were injected subcutaneously every 12 hours for a total of 3 times, and then the same mice were followed up to 8 weeks of age over time.
- SYTO GREEN is a low-affinity nucleic acid-binding substance that passively diffuses through living cell membranes and stains nucleic acids (Chen A & McConnell SK, Cell 82: 631-341, 1995). It has never been used in mice.
- a liver tissue section was prepared using this mouse in the same manner as in Example 1, and the arrangement was confirmed with a fluorescent stereomicroscope. SYTO GREEN-labeled residual hepatocytes showed almost the same distribution as the BrdU-labeled residual cells of Example 1 at the section level (FIG. 4).
- Example 5 Example of fluorescent labeling of tissue stem cells in living mice: large intestine
- Example 4 SYTO GREEN (50 nM, 100 ⁇ L / animal) was injected into a 2-week-old C57BL / 6 mouse (manufactured by Claire Japan) once intravenously, and after 4 weeks, survived in the same manner as in Example 4. The observation was continued with a fluorescent stereomicroscope. As shown in FIG. 6 (below), liver tissue stem cells could be labeled even in this simplified example. In addition, liver tissue sections were prepared in the same manner as in Example 1, and fluorescence immunohistological analysis with type IV collagen was performed. Observation with a confocal laser microscope revealed that all cell nuclei were stained in the liver immediately after labeling (upper left figure in Fig. 6), but only tissue stem cells could be detected in the liver after 4 weeks (figure 6). 6 Upper right figure, arrow). That is, the principle of the present invention could be confirmed even in detailed histological examination.
- Example 6b Application example of fluorescent labeling of tissue stem cells in living mice: Liver cancer stem cells
- DEN 50 ⁇ gZ mice
- SYTO GREEN 50 nM, 100 x L / mouse
- Fig. 12 shows several small SYTO G REEN bright cell populations that are considered small clusters of cancerous stem cells are found in the small lesions that can be judged as early cancer-forming foci. It was.
- the present invention can easily identify three types of cancer stem cells, normal stem cells, and normal cancer cells according to their luminance levels. That is, by this method, it is possible to clearly diagnose cancerous stem cells from an early stage at a level that cannot be visually detected.
- the liver of a 4-week-old mouse prepared in the same manner as in Example 4 was collected, and the cell suspension of liver cells was added to RPMI1640 medium as previously reported10.
- FCS / 0 Usi fetal serum
- 100 U / mL penicillin G and 100 mg / mL streptomycin were added to the culture medium (all manufactured by GIBC 0) (Yoneyama et al. J. Exp. Med. 193: 35-49, 2001).
- Freshly prepared hepatocyte suspension was immediately analyzed with a flow cytometer (COPAS cell sorter, Union Biometric Inc.). As shown in Fig. 7, fluorescence was effective even after hepatocyte separation using SYTO GREEN.
- SYTO GREEN high and SYTO GREEN negative cells were sorted one by one into a 96-well plate.
- the 96-well plate was not coated and cultured for 3 days in a serum-free medium for hepatocytes (H-marked atoZYME-SFM, manufactured by GIBCO), whereas SYTO GREEN negative cells did not form colonies.
- H-marked atoZYME-SFM manufactured by GIBCO
- SYTO GREEN negative cells did not form colonies.
- colony formation was observed (Fig. 7). Ie SYTO GREEN high cells The group was found to have extremely high growth ability without the coating of the medium or the addition of growth factors in the culture.
- the SYTO GREEN high cell group isolated and expanded in Example 7 was seeded in a 10 cm culture dish without coating and cultured for 24 hours. As a result, a single-layered hepatocyte cord-like structure was rapidly formed at the bottom of the dish, much like a liver tissue section (Fig. 8). It was shown that the SYTO GREEN high cell population isolated by this isolation method has the ability to construct a shape unique to the S warehouse.
- Human lung cancer-derived alveolar epithelial cell line A549 (J. Nat. Cancer Inst. 51: 1417-1423, 1973) was treated with 10% FCS, 100 U / mL penicillin G, and 100 mg / mL streptomycin in DMEM medium.
- SYTO GR EEN was added at a concentration of 5 ng / mL under the conditions of culturing in the added culture medium (all manufactured by GIBCO). Although all cell nuclei were labeled 1 hour after addition, the number of labeled cells was reduced to several percent despite being confluent after 1 week (Fig. 9).
- the cell group of SYTO GREEN high can be easily isolated using a cell sorter in the same manner as in Example 7.
- cancer cell line D54 derived from meningiomas a human brain tumor
- a DMEM medium containing 10% FCS, 100 U / mL penicillin G and 100 mg / mL streptomycin all manufactured by GI BCO.
- SYTO GREEN was added at a concentration of 5 ng / mL.
- all cell nuclei were labeled 1 hour after addition, the number of labeled cells decreased to several percent even though they were confluent after 4 days (Fig. 13). This process can be detected clearly and quickly with the flow cytometer on the diagram.
- a test substance or the like is added during culturing, only substances that selectively kill only cancerous stem cells can be easily screened. Isolation using a cell sorter is equally easy. Industrial applicability
- the experimental technique of the present invention is extremely simple and reproducible in any small laboratory in the world, and expands the base of stem cell research at once.
- human cell lines must be used, but if fluorescent dyes that are not toxic to humans are developed, stem cells can be monitored even in living individuals. This will be a joint work with the development and improvement of diagnostic imaging equipment (hard surface), but it will make ultra-early diagnosis of cancer a reality in the near future.
- the present invention has been developed as an antibody drug or RNAi drug that selectively treats "pathological stem cells" as a therapeutic target, and the development of cancer treatment with the first stem cell vaccine in the history of anthropology. Can be expected.
- the development of safer and more effective cell therapies can be expected by analyzing in detail the characteristics of the isolated stem cells, culture conditions, and whereabouts in vivo.
- hepatocyte cord sheets are easily formed by culturing, so it may be the best source to supply when creating an artificial liver tissue-engineering.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007501636A JPWO2007129428A1 (ja) | 2006-05-02 | 2006-12-26 | 幹細胞の単離方法 |
EP06843245A EP2022846A4 (en) | 2006-05-02 | 2006-12-26 | METHOD FOR ISOLATING A STEM CELL |
US11/576,380 US20090202564A1 (en) | 2006-05-02 | 2006-12-26 | Methods of isolating stem cells |
US13/314,776 US20120141984A1 (en) | 2006-05-02 | 2011-12-08 | Methods of isolating stem cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006128106 | 2006-05-02 | ||
JP2006-128106 | 2006-05-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/314,776 Continuation US20120141984A1 (en) | 2006-05-02 | 2011-12-08 | Methods of isolating stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007129428A1 true WO2007129428A1 (ja) | 2007-11-15 |
Family
ID=38667541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/325861 WO2007129428A1 (ja) | 2006-05-02 | 2006-12-26 | 幹細胞の単離方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20090202564A1 (ja) |
EP (1) | EP2022846A4 (ja) |
JP (2) | JPWO2007129428A1 (ja) |
WO (1) | WO2007129428A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013542957A (ja) * | 2010-11-02 | 2013-11-28 | オートロガス,エルエルシー | 非老化性心臓幹細胞の単離方法およびその使用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014025234A2 (ko) * | 2012-08-09 | 2014-02-13 | 연세대학교 산학협력단 | 암 줄기세포에 특이적으로 결합하는 핵산 앱타머 및 이의 용도 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005517441A (ja) * | 2002-02-19 | 2005-06-16 | メディポスト・カンパニー・リミテッド | 臍帯血由来の間葉幹細胞・前駆細胞の分離培養方法及び間葉組織への分化誘導方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003234688A1 (en) * | 2002-04-05 | 2003-10-27 | The Regents Of The University Of California | Method for isolating and measuring proliferation of long-term label retaining cells and stem cells |
-
2006
- 2006-12-26 JP JP2007501636A patent/JPWO2007129428A1/ja not_active Withdrawn
- 2006-12-26 WO PCT/JP2006/325861 patent/WO2007129428A1/ja active Application Filing
- 2006-12-26 EP EP06843245A patent/EP2022846A4/en not_active Withdrawn
- 2006-12-26 US US11/576,380 patent/US20090202564A1/en not_active Abandoned
-
2007
- 2007-11-26 JP JP2007304238A patent/JP2008148693A/ja active Pending
-
2011
- 2011-12-08 US US13/314,776 patent/US20120141984A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005517441A (ja) * | 2002-02-19 | 2005-06-16 | メディポスト・カンパニー・リミテッド | 臍帯血由来の間葉幹細胞・前駆細胞の分離培養方法及び間葉組織への分化誘導方法 |
Non-Patent Citations (16)
Title |
---|
BEACHY PA ET AL., NATURE, vol. 432, 2004, pages 324 - 331 |
CHEN A; MCCONNELL SK, CELL, vol. 82, 1995, pages 631 - 341 |
CLARKE MF., CANCER CHEMOTHER PHARMACOL, vol. 56, 2005, pages 64 - 68 |
CLARKE MF; FULLER M., CELL, vol. 124, 2006, pages 1111 - 1115 |
FUCHS E ET AL., CELL, vol. 116, 2004, pages 769 - 778 |
FUCHS E; SEGRE JA., CELL, vol. 100, 2000, pages 143 - 155 |
J. NAT. CANCER INST., vol. 51, 1973, pages 1417 - 1423 |
MORITA T.: "Kan Saibo no DNA Gosei-DNA-sa no Sentakuteki Bunri-", THE CELL, vol. 18, no. 2, 1986, pages 61 - 65, XP008100587 * |
MORRISON GR., ARCH. BIOCHEM. BIOPHYS, vol. 111, 1965, pages 448 |
ROBERTSON EJ., BIOLOGY OF REPRODUCTION, vol. 44, 1991, pages 238 - 245 |
RUTH KIRSCHSTEIN; LANA R SKIRBOLL, STEM CELLS: SCIENTIFIC PROGRESS AND FUTURE RESEARCH DIRECTIONS, 2001, pages 1 - 106 |
See also references of EP2022846A4 * |
SYTO: "Green-Fluorescent Nucleic Acid Stains. Product Information", MOLECULAR PROBES INC., vol. 18, no. 2, 2003, pages 15 - 19, XP008100735 * |
TAYLOR ET AL., CELL, vol. 102, 2000, pages 451 - 461 |
YANG X ET AL., INT J CANCER, vol. 118, 2006, pages 1869 - 1876 |
YONEYAMA ET AL., J. EXP. MED., vol. 193, 2001, pages 35 - 49 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013542957A (ja) * | 2010-11-02 | 2013-11-28 | オートロガス,エルエルシー | 非老化性心臓幹細胞の単離方法およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
JP2008148693A (ja) | 2008-07-03 |
US20090202564A1 (en) | 2009-08-13 |
JPWO2007129428A1 (ja) | 2009-12-24 |
EP2022846A4 (en) | 2010-06-23 |
US20120141984A1 (en) | 2012-06-07 |
EP2022846A1 (en) | 2009-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104483485B (zh) | 用于鉴定、扩增和去除成体干细胞和癌干细胞的方法 | |
CN101815522B (zh) | 诊断、预防或治疗与表达IL‑8或GRO‑α的细胞有关的疾病的组合物 | |
JP5645816B2 (ja) | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 | |
CN103189511B (zh) | 利用siRNA导入的新型hiPSC制作法 | |
CN102459576B (zh) | 用于调节干细胞的组合物和方法及其应用 | |
KR20140020863A (ko) | 종양 세포 및 조직 배양 | |
JP2019013243A (ja) | ヒト網膜前駆細胞の表現型プロファイル | |
CN102510719A (zh) | 用与细胞毒性化学治疗剂组合的内皮素受体抑制剂治疗脑转移 | |
Zheng et al. | Tumor–Stroma Interactions in Bone Metastasis: Molecular Mechanisms and Therapeutic Implications | |
WO2021253078A1 (en) | Process to produce photoreceptor cells | |
CN109152799A (zh) | 胰腺干细胞及其用途 | |
CN103237887A (zh) | 胚胎干细胞来源的心肌细胞以及包含所述心肌细胞作为活性成分的细胞治疗剂 | |
US20130011373A1 (en) | Side population cells in cardiac repair | |
WO2018025975A1 (ja) | インビトロで多能性幹細胞を分化誘導する方法 | |
KR20200005345A (ko) | 신장 스페로이드 및 그의 제조 방법 | |
WO2007129428A1 (ja) | 幹細胞の単離方法 | |
JP2008532474A (ja) | 胚性幹(es)細胞系での組織モデリング | |
CN109069545A (zh) | 神经干细胞及其用途 | |
US20070250942A1 (en) | Non-human transgenic mammals useful for identifying and assessing neural stem/progenitor cells | |
Crisanti et al. | Novel methods for delivery of cell-based therapies | |
US20210309729A1 (en) | Netrin g1 as a biomarker for enhancing tumor treatment efficacy | |
KR102296075B1 (ko) | epcam 유전자 변이 제브라피쉬 및 이의 용도 | |
WO2004097008A1 (en) | Method of generating and isolating tumour cells | |
JP5970721B2 (ja) | 抑制性神経前駆細胞の増殖、分離、移植、およびこの細胞の増殖促進物質 | |
Nabhan | Alveolar Stem Cells and Niches in Aging, Injury and Evolution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2007501636 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06843245 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11576380 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006843245 Country of ref document: EP |